Beta Drugs earnings increased in the first half of fiscal 2027, with revenue rising 29.2% year over year and profit after tax reaching INR34 crore. In earnings commentary released on October 22, 2026, management maintained its growth outlook despite a temporary production shutdown that shifted branded sales into the second half and persistent platinum supply constraints.
Key Takeaways
- First-half profit after tax rose a reported 45%, outpacing revenue growth.
- Management expects delayed branded sales to move into H2 after completing production debottlenecking.
- The export growth outlook was reduced to about 30% annually, reflecting the uneven timing of tenders.
Table of Contents
- Beta Drugs earnings show stronger profit growth
- Production recovery underpins the branded sales target
- Exports expand, but tender timing tempers guidance
- Receivables highlight the cash-collection challenge
- Conclusion
Beta Drugs earnings show stronger profit growth
Profit after tax increased to INR34 crore from a rounded INR24 crore a year earlier. Management reported growth of 45%, compared with the 29.2% increase in revenue.
The reported EBITDA margin was 23.18%, including other income, versus 22% excluding it. That distinction matters when assessing operating profitability: the higher figure is not solely a measure of earnings generated by the core business.
Management outlined sustained margins of 23%–24% and growth of 20%–25% over the next three to five years. It expects a more favorable business mix, greater scale and backward integration into active pharmaceutical ingredients, or APIs, to support profitability. These remain management expectations rather than achieved results.
| Item | Details |
|---|---|
| FY27 total revenue | Management expects more than INR535 crore. |
| FY27 branded oncology growth | Management maintained guidance of 20%–22%. |
| FY27 contract manufacturing revenue | Management target of INR180–190 crore. |
| FY27 export revenue | Management target of INR90–100 crore. |
| Nivian growth outlook | Management sees 30%–35% growth as achievable over the next two to three years. |
Production recovery underpins the branded sales target
The own-branded business grew 17% in H1 FY27, but second-quarter growth was flat. Ashutosh Shukla, Whole Time Director and Director of Sales & Marketing, said a temporary shutdown for debottlenecking shifted INR6–7 crore of sales into the second half.
Management said the debottlenecking exercise was complete and both factories were operating at optimal production. It expects branded sales of about INR80 crore in H2, compared with roughly INR62 crore a year earlier, supporting a full-year target of approximately INR150 crore.
Beta Drugs’ manufacturing facilities and API operations include an Adley Lab India API plant and formulation plants operated by Adley Formulations India and Beta Drugs. This existing manufacturing footprint provides context for management’s integration strategy, but does not establish the completion or timing of new projects.
Chairman and Managing Director Rahul Batra said a new plant intended to manufacture about 20 internally developed intermediates, currently sourced from China, was expected to go live by January 2027. Platinum API availability nevertheless remained a constraint, and management did not expect significant near-term growth in the platinum business.
Exports expand, but tender timing tempers guidance
Export sales increased to INR43 crore from INR16 crore when excluding a one-time opportunity in the prior-year comparison. Management lowered its longer-term export growth expectation to around 30% compounded annually from the previous 50%, explaining that tender awards can slip between financial years.
The company had 872 registrations in its pipeline. Batra said four European product dossiers had been filed after auditors introduced a requirement for filing before inspection. Management expected an EU GMP audit within two to four months, although its timing remained uncertain.
Acquired business Nivian delivered 75% year-over-year growth. Management put its current EBITDA margin at approximately 18%–18.5% and expects integration benefits to lift that to 23%–25%. Planned entry into recombinant products remains two to three years away.
Receivables highlight the cash-collection challenge
Receivable days increased to 116 from 113 as of March 31, 2026. Management linked the increase partly to longer collection periods in institutional tender business.
Typical credit periods vary substantially: contract manufacturing carries 75–90 days, while branded business generally carries 60–70 days. Batra said government business can take up to six months to pay. The distinction is important because revenue growth does not necessarily translate into cash receipts at the same pace.
Conclusion
The next milestones for Beta Drugs earnings are the expected recovery of delayed branded sales in H2 FY27 and the planned January 2027 start of the intermediates plant. Both remain forward-looking, while the EU audit schedule and platinum supplies remain unresolved.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
